Product Description
Emedastine is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Emedastine)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Morocco | Netherlands | Norway | Pakistan | Philippines | Poland | Portugal | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Hisamitsu
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Rhinitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-183844 | P2 |
Active |
Rhinitis, Allergic |
None |